Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 346 to 360 of 2548 results for methods

  1. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839]

    Awaiting development Reference number: GID-TA11276 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838]

    Awaiting development Reference number: GID-TA11275 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Galcanezumab for migraine [TSID10663]

    Awaiting development Reference number: GID-TA11311 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Gantenerumab for treating early Alzheimer's disease [TSID10668]

    Awaiting development Reference number: GID-TA11072 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037]

    Awaiting development Reference number: GID-TA11059 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]

    Awaiting development Reference number: GID-TA11076 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]

    Awaiting development Reference number: GID-TA11517 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]

    Awaiting development Reference number: GID-TA11470 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467]

    Awaiting development Reference number: GID-TA11305 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies [TSID10765]

    Awaiting development Reference number: GID-TA11050 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable [TSID10477]

    Awaiting development Reference number: GID-TA11271 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Treprostinil diethanolamine for treating pulmonary arterial hypertension [TSID11772]

    Awaiting development Reference number: GID-TA11123 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [TSID11781]

    Awaiting development Reference number: GID-TA11110 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Tiratricol for treating Allan–Herndon–Dudley syndrome [ID6217]

    Awaiting development Reference number: GID-TA11192 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Tislelizumab for untreated unresectable hepatocellular carcinoma [TSID10683]

    Awaiting development Reference number: GID-TA11053 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development